AKT1 and hepatocellular carcinoma: Consistent with these studies, we found that erlotinib could partly inhibit Elafin induced HCC metastasis and EGFR/AKT signalling activation, and the combination of erlotinib treatment and Elafin knockdown showed a synergetic suppressive effect on HCC metastasis.